Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers

Grants

Funding Acknowledgements

This work was supported by Cancer Research UK grants C12292/A11174 and C1287/A10118, NHMRC grants to GCT, and grants from the NIH (CA128978), and the U.S. Department of Defense Ovarian Cancer Idea award (W81XWH-10-1-0341) to FJC. The research leading to these results has received funding from the European Community's Seventh Framework Programme No. 223175 (HEALTH-F2-2009-223175); European Community's Seventh Framework Programme under grant agreement No. 223175 (HEALTH-F2-2009-223175). ACA is a CR-UK Senior Cancer Research Fellow, DFE is CR-UK Principal Research Fellow, GCT is a NHMRC Senior Principal Research Fellow and JS is Chairholder of the Canada Research Chair in Oncogenetics. This work was supported by the Canadian Institutes of Health Research for the "CIHR Team in Familial Risks of Breast Cancer" program(grant number CRN_87521); and the Canadian Breast Cancer Research Alliance (grant number 019511)Breast Cancer Family Registry (BCFR): was supported by the National Cancer Institute, National Institutes of Health under RFA-CA-06-503 and through cooperative agreements with members of the Breast Cancer Family Registry and Principal Investigators, including Cancer Care Ontario (U01 CA69467), Columbia University (U01 CA69398), Fox Chase Cancer Center (U01 CA69631), HuntsmanCancer Institute (U01 CA69446), Northern California Cancer Center (U01CA69417), University of Melbourne (U01 CA69638), and Research Triangle Institute Informatics Support Center (RFP No. N02PC45022-46). The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the BCFR, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the BCFR.BRCA-genemutations and breast cancer in South Africanwomen (BMBSA): was supported by grants from the Cancer Association of South Africa (CANSA) to Elizabeth J. van Rensburg.Copenhagen Breast Cancer Study (CBCS): was supported by the Neye Foundation.Spanish National Cancer Center (CNIO). This study was partially supported by Fundacion Mutua Madrilena, Asociacion Espanola Contra el Cancer, the Spanish Minestry of Science and Innovation FIS PI08/1120 and Cancer Network RD06/0020/1060. Funded in part by the Basque Foundation for Health Innovation and Research (BIOEF: BIO07/CA/006).CONsorzio Studi Italiani Tumori Ereditari Alla Mammella (CONSIT TEAM) was supported by grants from Associazione Italiana per la Ricerca sul Cancro (4017) and by funds from Italian citizens who allocated the 5 x 1,000 share of their tax payment in support of the Fondazione IR-CCS Istituto Nazionale Tumori, according to Italian laws (INT-Institutional strategic projects "5 x 1,000") to PP. Supported by grants from Ministero della Salute ("Progetto Tevere"-Linea 1 RC D/08/02B-"Progetto Tumori Femminili"-F/08/0PZ-Linea1 RC CORR/08) to SM. Supported by grants from Associazione Italiana per la Ricerca sul Cancro (8713) to LO. Supported by grants from Fondazione Italiana per la Ricerca sul Cancro (Special Project "Hereditary tumors"), Ministero della Salute (RFPS-2006-3-340203, Extraordinary National Cancer Program 2006 "Alleanza contro il Cancro", and "Progetto Tumori Femminili") and Ministero dell'Universita' e Ricerca (RBLAO3-BETH) to PR.Deutsches Krebsforschungszentrum (DKFZ) study: was supported by the DKFZ.Epidemiological study of BRCA1 & BRCA2 mutation carriers (EMBRACE) was supported by Cancer Research UK Grants (C1287/A10118 and C1287/A11990). D. Gareth Evans and Fiona Lalloo are supported by an NIHR grant to the Biomedical Research Centre, Manchester. The Investigators at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust are supported by an NIHR grant to the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. Ros Eeles, Elizabeth Bancroft, and Lucia D'Mello were also supported by Cancer Research UK Grant (C5047/A8385).Fox Chase Cancer Center (FCCC): was supported by the National Institutes of Health (U01 CA69631, 5U01 CA113916, R01 CA140323 to A. K. G.); the Ovarian Cancer Research Fund, and the Eileen Stein Jacoby Fund. The author acknowledges support from The University of Kansas Cancer Center and the Kansas Bioscience Authority Eminent Scholar Program. A. K. G. is the Chancellors Distinguished Chair in Biomedical Sciences endowed Professor. The German Consortium of Hereditary Breast and Ovarian Cancer (GC-HBOC): was supported by a grant of the German Cancer Aid (grant 109076) and by the Centre of Molecular Medicine Cologne (CMMC).Genetic Modifiers of cancer risk in BRCA1/2 mutation carriers (GEMO) study (Cancer Genetics Network "Groupe Genetique et Cancer", Federation Nationale des Centres de Lutte Contre le Cancer, France) was supported by the Ligue National Contre le Cancer; Association for International Cancer Research Grant (AICR-07-0454); and the Association "Le cancer du sein, parlons-en!" Award.Georgetown. CI received support from the Familial Cancer Registry at Georgetown University (NIH/NCI grant P30-CA051008), the Cancer Genetics Network (HHSN261200744000C), and Swing For the Cure. Gynecologic Oncology Group (GOG): KAP is the Cancer Council Victoria, Colebatch Clinical Research Fellow.The Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON). The HEBON study is supported by the Dutch Cancer Society grants NKI1998-1854, NKI2004-3088, NKI2007-3756 and the ZonMW grant 91109024.Hospital Clinico San Carlos (HCSC): was supported by The National Institute of Health Carlos III (RTICC 06/0020/0021).Helsinki Breast Cancer Study (HEBCS): was supported by the Helsinki University Central Hospital Research Fund, Academy of Finland (132473), the Finnish Cancer Society, and the Sigrid Juselius Foundation.The Hong Kong Hereditary Breast Cancer Family Registry (HRBCP): thanks the Dr. Ellen Li Charitable Foundation and Kuok Foundation for grant support.Hungarian Breast and Ovarian Cancer Study (HUNBOCS) was supported by Hungarian Research Grant KTIA-OTKA CK-80745 to Edith Olah.International Hereditary Cancer Center (IHCC): was supported by the State Committee for Scientific Research (PBZ_KBN_122/P05/2004). Katarzyna Jaworska is a fellow of International PhD program, Postgraduate School of Molecular Medicine, Warsaw Medical University, supported by the Polish Foundation of Science.Iceland Landspitali-University Hospital (ILUH): The ILUH group was supported by a grant from the Icelandic Association "Walking for Breast Cancer Research" and by the Landspitali University Hospital Research Fund.Istituto Oncologico Veneto Hereditary Breast and Ovarian Cancer Study (IOVHBOCS) was supported by Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR), and "Ministero della Salute" ("Progetto Tumori Femminili and grant numbersRFPS 2006-5-341353, ACC2/R6.9").Kathleen Cuningham Consortium for Research into Familial Breast Cancer (KCONFAB) was supported by grants from the National Breast Cancer Foundation, the National Health and Medical Research Council (NHMRC), and by the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia. ABS is a Senior Research Fellow of the NHMRC.The research of the MAGIC consortium at the University of Pennsylvania was funded by RO1-CA083855 and RO1-CA102776 to TRR.Mayo Clinic Study (MAYO) was supported by the National Institutes of Health (R01 CA128978 and P50 CA116201); the Komen race for the cure (KG081527); the Breast Cancer Research Foundation and the U.S. Department of Defense Ovarian Cancer Idea award (W81XWH-10-1-0341).Memorial Sloane Kettering Cancer Center (MSKCC) was supported by the Breast Cancer Research Foundation and the Lomangino Family Research Fund.National Cancer Institute (NCI): was supported by the Intramural Research Program of the US National Cancer Institute at the National Institutes of Health, and by support services contracts NO2-CP-11019-50 and N02-CP-65504 with Westat, Inc, Rockville, MD to PLM and MHG.N.N. Petrov Institute of Oncology (NNPIO): was supported by the Russian Foundation for Basic Research (grant numbers 10-04-92601, 10-04-92110, 11-04-00227), the Federal Agency for Science and Innovations (contract 16.512.11.2237), the Commission of the European Communities (grant number PITN-GA-2009-238132), and through a Royal Society International Joint grant (JP090615).Ontario Cancer Genetics Network (OCGN): was supported by Cancer Care Ontario, Canada (ILA); and the National Cancer Institute, National Institutes of Health under RFA-CA-06-503 and through cooperative agreements with members of the Breast Cancer Family Registry and PIs. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the CFR, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the CFR.The Ohio State University Clinical Cancer Genetics (OSUCCG): was supported by the Ohio State University Comprehensive Cancer Center.Pisa Breast Cancer Study (PBCS): was supported by Fondazione Cassa di Risparmio di PisaGrant n. 122/07 and grant 2010 from ITT (Istituto Toscano Tumori).Swedish Breast Cancer Study (SWE-BRCA): was supported by the Swedish Cancer Society.Beckman Research Institute City of Hope (BRICOH) was supported by the National Institutes of Health (R01 CA74415 to SLN and YCD) University of California, Los Angeles (UCLA) was supported by funding from the Jonsson Comprehensive Cancer Center Foundation.University of California San Francisco (UCSF): was supported by the Clinical and Translational Science Institute at the University of California, San Francisco (to MSB).UK and Gilda Radner Familial Ovarian Cancer Registries (UKGRFOCR): UKFOCR was supported by a project grant from CRUK to PP. We would like to acknowledge the Roswell Park Alliance Foundation for their continued support of the Gilda Radner Ovarian Family Cancer Registry.University of Pennsylvania (UPENN) was supported by Breast Cancer Research Foundation (BRCF) to KLN and Komen Foundation for the Cure to SMD.Women's Cancer Program (WCP): was supported in part by the American Cancer Society Early Detection Professorship (SIOP-06-258-01-COUN).Breast Cancer Family Registry (BCFR): Samples from the FCCC, HCI, and NCCC were processed and distributed by the Coriell Institute for Medical Research.Beckman Research Institute of City of Hope was supported by the National Institutes of Health (R01 CA74415 to SLN)) and the Morris and Horowitz Families Endowment.